<DOC>
	<DOCNO>NCT00165789</DOCNO>
	<brief_summary>This randomize , double-blind , two treatment , two group , parallel group study . Subjects randomize one two treatment group ( E2007 Placebo ) 3 1 ratio receive treatment total ten week ( Days 1 70 ) .</brief_summary>
	<brief_title>A Study Explore Safety And Tolerability Doses E2007 Up Maximum 8 mg In Patients With Parkinson 's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subjects race great equal 30 year age Have diagnosis idiopathic Parkinson 's disease . Subjects fulfill UK Parkinson 's Disease Society Brain Bank Clinical Diagnostic criterion ( Queen Square criterion ) rating 2 4 Hoehn Yahr scale 'off ' state . Receiving optimized regimen antiParkinsonian treatment stable least four week baseline . The regimen consider stable `` require '' `` demand '' dose routinely use regular use apomorphine liquid form levodopa . Taking levodopa levodopacontaining medication ( e.g . cobeneldopa , cocareldopa ) least three time daily good response levodopa dose evidence patient diary medical note . Consistently experience endofdose `` wearingoff '' motor fluctuation . Subjects : score great equal 1 Question 39 ( What proportion wake day patient `` '' average ? ) full UPDRS screening . least 2.5 hour `` '' time average per day record patient diary baseline . Willing able provide write informed consent adhere protocol requirement , include completion patient diary . Receiving treatment medication know induce CYP3A4 activity Previous stereotactic surgery ( e.g . pallidotomy , subthalamic nucleus deep brain stimulation ) Parkinson 's disease Received investigational product within four week prior screen participate previous study E2007 . Clinically significant cognitive impairment [ minimental state examination ( MMSE ) less 24 fulfil DSM IV criterion dementia due Parkinson 's disease ] . Active hepatic disease , significantly reduce hepatic function significantly elevate liver enzyme ( abnormal bilirubin serum transaminase level 1.5 time upper limit normal range ) . Clinically significant ECG abnormality , include prolonged QTc ( define QTc great equal 450 msec male great equal 470 msec female use Fridericia 's correction ) . Clinically significant , cardiovascular , metabolic , respiratory , renal , endocrinological , gastrointestinal disease , psychiatric disorder , bacterial viral infection within previous 30 day . History drug alcohol abuse . Women pregnant lactating . Any condition could , opinion investigator , place subject increase risk likely prevent completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>